Sarcomas in hereditary retinoblastoma

Clinical Sarcoma Research

Margaret A Tucker²  Sara J Schonfeld¹  Ruth A Kleinerman¹ 

[1] Epidemiology and Biostatistics Program Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, 6120 Executive Boulevard, Rockville, MD 20852, USA;Human Genetics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, 6120 Executive Boulevard, Rockville, MD 20852, USA

关键词: Hereditary;    RB1 gene;    Epidemiology;    Radiotherapy;    Bone sarcoma;    Soft tissue sarcoma;    Retinoblastoma;   

Others  :  862949
DOI  :  10.1186/2045-3329-2-15

 received in 2011-10-07, accepted in 2012-01-23,  发布年份 2012

【 摘 要 】

Children diagnosed with the hereditary form of retinoblastoma (Rb), a rare eye cancer caused by a germline mutation in the RB1 tumor suppressor gene, have excellent survival, but face an increased risk of bone and soft tissue sarcomas. This predisposition to sarcomas has been attributed to genetic susceptibility due to inactivation of the RB1 gene as well as past radiotherapy for Rb. The majority of bone and soft tissue sarcomas among hereditary Rb survivors occur in the head, within the radiation field, but they also occur outside the radiation field. Sarcomas account for almost half of the second primary cancers in hereditary Rb survivors, but they are very rare following non-hereditary Rb. Sarcomas among hereditary Rb survivors arise at ages similar to the pattern of occurrence in the general population. There has been a trend over the past two decades to replace radiotherapy with chemotherapy and other focal therapies (laser or cryosurgery), and most recently, chemosurgery in order to reduce the incidence of sarcomas and other second cancers in Rb survivors. Given the excellent survival of most Rb patients treated in the past, it is important for survivors, their families and health care providers to be aware of the heightened risk for sarcomas in hereditary patients.

【 授权许可】

   
2012 Kleinerman et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Harbour JW: Molecular basis of low-penetrance retinoblastoma. Arch Ophthalmol 2001, 119:1699-1704.
• [2]Burkhart DL, Sage J: Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer 2008, 8:671-682.
• [3]Knudson AG Jr: Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 1971, 68:820-823.
• [4]Little MP, Kleinerman RA, Stiller CA, Li G: Kroll ME. Murphy MF: Analysis of retinoblastoma age incidence data using a fully stochastic cancer model. Int J Cancer; 2011.
• [5]SEER: Cancer Statistics Review. 2008. [ http://seer.cancer.gov/csr/1975_2008 webcite]
• [6]Marees T, Moll AC, Imhof SM, de Boer MR, Ringens PJ, van Leeuwen FE: Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up. J Natl Cancer Inst 2008, 100:1771-1779.
• [7]Kleinerman RA, Tucker MA, Tarone RE, Abramson DH, Seddon JM, Stovall M, Li FP, Fraumeni JF Jr: Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. J Clin Oncol 2005, 23:2272-2279.
• [8]Draper GJ, Sanders BM, Kingston JE: Second primary neoplasms in patients with retinoblastoma. Br J Cancer 1986, 53:661-671.
• [9]Eng C, Li FP, Abramson DH, Ellsworth RM, Wong FL, Goldman MB, Seddon J, Tarbell N, Boice JD Jr: Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst 1993, 85:1121-1128.
• [10]Fletcher O, Easton D, Anderson K, Gilham C, Jay M, Peto J: Lifetime risks of common cancers among retinoblastoma survivors. J Natl Cancer Inst 2004, 96:357-363.
• [11]Wong FL, Boice JD Jr, Abramson DH, Tarone RE, Kleinerman RA, Stovall M, Goldman MB, Seddon JM, Tarbell N, Fraumeni JF Jr, Li FP: Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA 1997, 278:1262-1267.
• [12]Yu CL, Tucker MA, Abramson DH, Furukawa K, Seddon JM, Stovall M, Fraumeni JF Jr, Kleinerman RA: Cause-specific mortality in long-term survivors of retinoblastoma. J Natl Cancer Inst 2009, 101:581-591.
• [13]Hawkins MM, Wilson LM, Burton HS, Potok MH, Winter DL, Marsden HB, Stovall MA: Radiotherapy, alkylating agents, and risk of bone cancer after childhood cancer. J Natl Cancer Inst 1996, 88:270-278.
• [14]Tucker MA, D'Angio GJ, Boice JD Jr, Strong LC, Li FP, Stovall M, Stone BJ, Green DM, Lombardi F, Newton W, et al.: Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med 1987, 317:588-593.
• [15]Jenkinson HC, Winter DL, Marsden HB, Stovall MA, Stevens MC, Stiller CA, Hawkins MM: A study of soft tissue sarcomas after childhood cancer in Britain. Br J Cancer 2007, 97:695-699.
• [16]Reulen RC, Frobisher C, Winter DL, Kelly J, Lancashire ER, Stiller CA, Pritchard-Jones K, Jenkinson HC, Hawkins MM: Long-term risks of subsequent primary neoplasms among survivors of childhood cancer. JAMA 2011, 305:2311-2319.
• [17]Woo KI, Harbour JW: Review of 676 second primary tumors in patients with retinoblastoma: association between age at onset and tumor type. Arch Ophthalmol 2010, 128:865-870.
• [18]Kleinerman R, Yu CL, Little MP, Abramson DH, Seddon JH, Tucker MA: Variation of second cancer risk by family history of retinoblastoma among long-term survivors. Journal of Clin Oncol 2012, 30:950-957. in press
• [19]Cope JU, Tsokos M, Miller RW: Ewing sarcoma and sinonasal neuroectodermal tumors as second malignant tumors after retinoblastoma and other neoplasms. Med Pediatr Oncol 2001, 36:290-294.
• [20]Moll AC, Imhof SM, Schouten-Van Meeteren AY, Kuik DJ, Hofman P, Boers M: Second primary tumors in hereditary retinoblastoma: a register-based study, 1945–1997: is there an age effect on radiation-related risk? Ophthalmology 2001, 108:1109-1114.
• [21]Chauveinc L, Mosseri V, Quintana E, Desjardins L, Schlienger P, Doz F, Dutrillaux B: Osteosarcoma following retinoblastoma: age at onset and latency period. Ophthalmic Genet 2001, 22:77-88.
• [22]Kleinerman RA, Tucker MA, Abramson DH, Seddon JM, Tarone RE, Fraumeni JF Jr: Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma. J Natl Cancer Inst 2007, 99:24-31.
• [23]Toro JR, Travis LB, Wu HJ, Zhu K, Fletcher CD, Devesa SS: Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: An analysis of 26,758 cases. Int J Cancer 2006, 119:2922-2930.
• [24]Francis JH, Kleinerman RA: Seddon JM. Abramson DH: Increased risk of secondary uterine leiomyosarcoma in hereditary retinoblastoma. Gynecol Oncol; 2011.
• [25]Dei Tos AP, Maestro R, Doglioni C, Piccinin S, Libera DD, Boiocchi M, Fletcher CD: Tumor suppressor genes and related molecules in leiomyosarcoma. Am J Pathol 1996, 148:1037-1045.
• [26]Venkatraman L, Goepel JR, Steele K, Dobbs SP, Lyness RW, McCluggage WG: Soft tissue, pelvic, and urinary bladder leiomyosarcoma as second neoplasm following hereditary retinoblastoma. J Clin Pathol 2003, 56:233-236.
• [27]Bleoo SL, Godbout R, Rayner D, Tamimi Y, Moore RB: Leiomyosarcoma of the bladder in a retinoblastoma patient. Urol Int 2003, 71:118-121.
• [28]Brucker B, Ernst L, Meadows A, Zderic S: A second leiomyosarcoma in the urinary bladder of a child with a history of retinoblastoma 12 years following partial cystectomy. Pediatr Blood Cancer 2006, 46:811-814.
• [29]Cebulla CM, Kleinerman RA, Alegret A, Kulak A, Dubovy SR, Hess DJ, Murray TG: Rapid Appearance of Rhabdomyosarcoma after Radiation and Chemotherapy for Retinoblastoma: A Clinicopathologic Correlation. Retin Cases Brief Rep 2009, 3:343-346.
• [30]Li FP, Abramson DH, Tarone RE, Kleinerman RA, Fraumeni JF Jr, Boice JD Jr: Hereditary retinoblastoma, lipoma, and second primary cancers. J Natl Cancer Inst 1997, 89:83-84.
• [31]Rieder H, Lohmann D, Poensgen B, Fritz B, Aslan M, Drohm D, Strombach Angersbach FJ, Rehder H: Loss of heterozygosity of the retinoblastoma (RB1) gene in lipomas from a retinoblastoma patient. J Natl Cancer Inst 1998, 90:324-326.
• [32]Genuardi M, Klutz M, Devriendt K, Caruso D, Stirpe M, Lohmann DR: Multiple lipomas linked to an RB1 gene mutation in a large pedigree with low penetrance retinoblastoma. Eur J Hum Genet 2001, 9:690-694.
• [33]Friend SH, Bernards R, Rogelj S, Weinberg RA, Rapaport JM, Albert DM, Dryja TP: A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 1986, 323:643-646.
• [34]Stratton MR, Williams S, Fisher C, Ball A, Westbury G, Gusterson BA, Fletcher CD, Knight JC, Fung YK, Reeves BR, et al.: Structural alterations of the RB1 gene in human soft tissue tumours. Br J Cancer 1989, 60:202-205.
• [35]Friend SH, Horowitz JM, Gerber MR, Wang XF, Bogenmann E, Li FP, Weinberg RA: Deletions of a DNA sequence in retinoblastomas and mesenchymal tumors: organization of the sequence and its encoded protein. Proc Natl Acad Sci U S A 1987, 84:9059-9063.
• [36]Bookstein R, Lee WH: Molecular genetics of the retinoblastoma suppressor gene. Crit Rev Oncog 1991, 2:211-227.
• [37]Helman LJ, Meltzer P: Mechanisms of sarcoma development. Nat Rev Cancer 2003, 3:685-694.
• [38]Gobin YP, Dunkel IJ, Marr BP, Brodie SE, Abramson DH: Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. Arch Ophthalmol 2011, 129:732-737.
• [39]Turaka K, Shields CL, Meadows AT, Leahey A: Second malignant neoplasms following chemoreduction with carboplatin, etoposide, and vincristine in 245 patients with intraocular retinoblastoma. Pediatr Blood Cancer 2012, 59:121-125.
• [40]Abramson DH: Chemosurgery for retinoblastoma: what we know after 5 years. Arch Ophthalmol 2011, 129:1492-1494.
• [41]de Graaf P, Goricke S, Rodjan F, Galluzzi P, Maeder P, Castelijns JA, Brisse HJ: Guidelines for imaging retinoblastoma: imaging principles and MRI standardization. Pediatr Radiol 2012, 42:2-14.
• [42]Meadows AT: Retinoblastoma survivors: sarcomas and surveillance. J Natl Cancer Inst 2007, 99:3-5.
• [43]Dommering CJ, Marees T, van der Hout AH, Imhof SM, Meijers-Heijboer H, Ringens PJ, van Leeuwen FE, Moll AC: RB1 mutations and second primary malignancies after hereditary retinoblastoma. Fam Cancer 2011, 11:225-233.
• [44]MacCarthy A, Bayne AM, Draper GJ, Eatock EM, Kroll ME, Stiller CA, Vincent TJ, Hawkins MM, Jenkinson HC, Kingston JE, et al.: Non-ocular tumours following retinoblastoma in Great Britain 1951 to 2004. Br J Ophthalmol 2009, 93:1159-1162.
• [45]Marees T, van Leeuwen FE, de Boer MR, Imhof SM, Ringens PJ, Moll AC: Cancer mortality in long-term survivors of retinoblastoma. Eur J Cancer 2009, 45:3245-3253.
• [46]Acquaviva A, Ciccolallo L, Rondelli R, Balistreri A, Ancarola R, Cozza R, Hadjistilianou D, Francesco SD, Toti P, Pastore G, et al.: Mortality from second tumour among long-term survivors of retinoblastoma: a retrospective analysis of the Italian retinoblastoma registry. Oncogene 2006, 25:5350-5357.